Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Daiichi Sankyo
Medtronic
Deloitte
Farmers Insurance
Boehringer Ingelheim
US Army
Federal Trade Commission
Citi

Generated: October 18, 2017

DrugPatentWatch Database Preview

Pegvisomant - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for pegvisomant and what is the scope of pegvisomant patent protection?

Pegvisomant
is the generic ingredient in one branded drug marketed by Pharmacia And Upjohn and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Pegvisomant has fifty-four patent family members in fifteen countries and eight supplementary protection certificates in eight countries.

One supplier is listed for this compound.

Summary for Generic Name: pegvisomant

US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list27
Therapeutic Class:Hormonal Agents, Suppressant (Pituitary)
Drug Prices:see low prices
DailyMed Link:pegvisomant at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-002Mar 25, 2003RXYesYes► Subscribe► SubscribeY ► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-003Mar 25, 2003RXYesYes► Subscribe► SubscribeY ► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-004Jul 31, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-001Mar 25, 2003RXYesYes► Subscribe► SubscribeY ► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-005Jul 31, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: pegvisomant

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-001Mar 25, 2003► Subscribe► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-003Mar 25, 2003► Subscribe► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-003Mar 25, 2003► Subscribe► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-003Mar 25, 2003► Subscribe► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-004Jul 31, 2014► Subscribe► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-001Mar 25, 2003► Subscribe► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-002Mar 25, 2003► Subscribe► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-004Jul 31, 2014► Subscribe► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-003Mar 25, 2003► Subscribe► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-002Mar 25, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: pegvisomant

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,780,279 Method of selection of proteolytic cleavage sites by directed evolution and phagemid display► Subscribe
6,136,563 Human growth hormone variants comprising amino acid substitutions► Subscribe
6,040,136 Enrichment method for variant proteins with altered binding properties► Subscribe
6,013,478 Method for identifying active domains and amino acid residues in polypeptides and hormone variants► Subscribe
6,428,954 Method for identifying active domains and amino acid residues in polypeptides and hormone variants► Subscribe
5,534,617 Human growth hormone variants having greater affinity for human growth hormone receptor at site 1► Subscribe
5,834,598 Human growth hormone variants► Subscribe
6,451,561 Growth hormone variants► Subscribe
6,022,711 Human growth hormone variants having enhanced affinity for human growth hormone receptor at site 1► Subscribe
5,846,765 Identification of novel substrates► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: pegvisomant

Country Document Number Estimated Expiration
Japan3681666► Subscribe
European Patent Office1568772► Subscribe
Japan3765959► Subscribe
Portugal1568772► Subscribe
Japan2004121261► Subscribe
European Patent Office0564531► Subscribe
Netherlands300210► Subscribe
Canada2658039► Subscribe
Japan3693668► Subscribe
Japan2002136295► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: PEGVISOMANT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
8Finland► Subscribe
C/GB05/047United Kingdom► SubscribePRODUCT NAME: PEGVISOMANT, OPTIONALLY IN THE FORM OF A PEGYLATION VARIANT; REGISTRATION NO/DATE: EU/1/02/240/001 - 003 20021113
0851925/01Switzerland► SubscribeFORMER REPRESENTANTIVE: BOVARD AG PATENTANWAELTE, CH
C0043France► SubscribePRODUCT NAME: PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001-003 20021113
C029/2005Ireland► SubscribeSPC029/2005: 20061023, EXPIRES: 20171112
0210Netherlands► Subscribe300210, 20160920, EXPIRES: 20171112
204Luxembourg► Subscribe91204, EXPIRES: 20171113
2005 00043Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Cerilliant
Moodys
Colorcon
Merck
Argus Health
Covington
Dow
Fuji
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot